Related Experiment Video
Updated: Mar 15, 2026
05:55
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
7.2K
The HBV Drugs Work: Now What?
1Professor of Surgery and Internal Medicine, John S. Najarian Clinical Chair Head Division of Transplantation, Executive Medical Director Solid Organ Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
The American Journal of Gastroenterology
|September 2, 2016
Summary
Antiviral therapies for Hepatitis B virus (HBV) suppress the virus but fail to establish long-term immune control. Further research is needed to understand and restore HBV immunity for durable viral suppression.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Current chemotherapeutic agents for Hepatitis B virus (HBV) effectively suppress viral replication when administered.
- These therapies do not induce durable, long-term immunological control against HBV.
- A small subset of patients achieve sustained control after prolonged treatment, but most do not.
Purpose of the Study:
- To investigate the limitations of current HBV therapies in achieving durable immune control.
- To explore the immunological defects underlying persistent HBV infection.
- To identify strategies for reconstituting innate or adaptive immunity for sustained viral suppression.
Main Methods:
- Analysis of patient data following 3 years of effective anti-HBV therapy.
- Assessment of virological markers (HBV-DNA, HBsAg) and liver enzymes.
- Evaluation of immune responses in patients with and without sustained viral control.
Main Results:
- Effective HBV suppression was achieved in the majority of patients during therapy.
- Only a small percentage of patients maintained controlled viral markers and liver enzymes post-therapy.
- The majority of patients did not achieve durable immunological control despite effective viral suppression.
Conclusions:
- Current antiviral treatments for HBV are insufficient for establishing long-term immune-mediated viral control.
- Understanding and addressing defects in the host immune response are critical for developing effective HBV therapies.
- Strategies to reconstitute innate and/or adaptive immunity are necessary to achieve durable suppression of Hepatitis B virus.
Related Concept Videos
01:29Viruses with RNA Genomes
1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
01:10Retrovirus Life Cycles
50.3K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.3K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
01:29Immune Response Against Viral Pathogens
2.4K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.4K
01:51Mechanisms of Retrovirus-induced Cancers
7.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K